“If we can eliminate these side effects, it could change the life of patients with Parkinson’s.”
Science Daily reports that designing drugs for Parkinson’s is difficult because of the progressive nature of the disease and the involvement of the neurotransmitter dopamine.
There are five types of dopamine receptors and finding a compound that only interacts with one desired receptor is difficult.
This new study tried to find a compound only binding to one dopamine receptor, specifically dopamine receptor number three (D3).